Brief: Cabaletta Bio Receives FDA Clearance Of CABA-201 IND Application For Treatment Of Generalized Myasthenia Gravis
06/11/2023 12:10
Nov 6 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO RECEIVES FDA CLEARANCE OF CABA-201 IND
APPLICATION
FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS
Source text for Eikon: ID:nGNX8RZ3H7
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity